What is Semax pharmacokinetics?: half-life, bioavailability, and duration of action

Pharmacokinetics is the field of science that studies what happens to a substance in the body – how it is absorbed, where it goes, how it breaks down, and how long it remains active. For Semax, this picture is more complex than a simple measure of its duration of action in the blood.

Semax is a synthetic heptapeptide – an artificially created chain of seven amino acids. Its structure was intentionally designed to be more resistant to degradation than the natural hormone fragment it was based on. At the end of the molecule, a short three-amino-acid tail, called Pro-Gly-Pro, was added precisely to extend the peptide's biological activity time in the body.

To fully understand Semax's behavior over time, researchers analyzed its absorption, speed of brain penetration, breakdown mechanisms, activity of metabolic products, and the actual duration of its effects. Each of these elements contributes to a pharmacokinetic profile much more complex than a single half-life number would suggest.

It should be noted that almost all available pharmacokinetic data comes from animal studies—primarily in rats—using radiolabeled versions of the peptide to track its path in the body. Direct pharmacokinetic measurements in humans are very limited.

How is Semax absorbed and how quickly does it reach the brain?

Semax reaches the brain exceptionally quickly after intranasal administration. In studies on rats using a radioactively labeled version of the peptide, intranasal administration at a dose of 50 micrograms per kilogram of body weight allowed Semax to be detected in brain tissue as early as 2 minutes after administration [1]. Approximately 80% of the substance reaching the brain at this early stage was intact, native Semax, rather than its metabolic fragments [1]. This confirms that the parent molecule itself—and not just its degradation products—reaches the brain rapidly and in significant quantities.

This rapid access to the brain is possible because the nose provides a direct pathway to the brain via the olfactory tract – the neural network responsible for the sense of smell. This pathway completely bypasses the bloodstream and the blood-brain barrier, allowing intranasally administered peptides to reach brain tissue much more effectively than through other routes of administration.

The speed of Semax's biological effects matches its rapid brain penetration. Changes in neurotrophic gene activity—genes responsible for producing proteins that support brain cell growth and survival—were detectable in the hippocampus and frontal cortex of rats as early as 20 minutes after a single intranasal dose [2]. In healthy volunteers, brain imaging studies using resting-state functional MRI, a technique that measures brain activity by detecting changes in blood flow, showed measurable changes in brain network activity just 5 and 20 minutes after intranasal administration of Semax [3]. This provides direct evidence from human studies that Semax engages the central nervous system within minutes of intranasal administration.

What is the half-life of Semax?

The half-life of Semax as an intact molecule in biological fluids is relatively short – as with most peptides – however, the total duration of biological activity extends significantly beyond this point. Half-life is the time it takes for half of a substance to decompose or be removed from the body.

In laboratory studies analyzing the degradation of Semax in the presence of rat brain cell membrane material, the intact molecule exhibited a half-life exceeding one hour [4]. This is significantly longer than many endogenous brain signaling peptides, which can be degraded within seconds to minutes.

Researchers have identified enzymes in rat blood and serum responsible for the breakdown of Semax. The main ones are aminopeptidases – particularly sensitive to a compound called bestatin – and an enzyme called angiotensin-converting enzyme (ACE). These enzymes are responsible for most of the Semax-degrading activity in the blood [5]. The process begins at the N-terminal end of the molecule – the beginning of the amino acid chain – where the first two amino acids, methionine and glutamate, are cleaved off first, forming intermediate fragments that are themselves biologically active [5].

It is worth clearly emphasizing one key fact: no published pharmacokinetic studies in humans have established the exact value of Semax's plasma half-life in humans. The values given in non-specialist internet sources do not come from peer-reviewed scientific research and should be approached with caution. What the published scientific literature confirms is that the intact molecule is relatively quickly broken down in biological fluids, its main breakdown products retain their own biological activity, and the total pharmacological action time of Semax is significantly longer than would be suggested by the removal of the parent molecule alone.

How is Semax metabolized?

Semax is metabolized – broken down – primarily through a stepwise process where enzymes sequentially cleave amino acids from the N-terminal end of the chain. Importantly, this breakdown does not simply mean Semax is deactivated. Instead, a series of smaller fragments is produced, each retaining its own biological activity.

The main metabolic pathway proceeds as follows: enzymes called dipeptidyl aminopeptidases and aminopeptidases first cleave two N-terminal amino acids—methionine and glutamate—from the Semax molecule. This results in the formation of a five-amino acid fragment, HFPGP (His-Phe-Pro-Gly-Pro), which is the main breakdown intermediate. HFPGP is then further broken down into a three-amino acid fragment, PGP (Pro-Gly-Pro), which is the main final metabolic product [4, 6].

Studies using radioactively labeled Semax confirmed that HFPGP and PGP are the main degradation products. The pattern of metabolite formation differed slightly between glial cells—support cells of the brain—and neurons, suggesting that different cell types process Semax somewhat differently [6].

Comparative studies of the distribution in nasal tissue, brain microsomal fractions, and rat blood showed that the C-terminal fragment of PGP—the tail of the molecule—is significantly more resistant to enzymatic degradation than the N-terminal fragment derived from ACTH. This means that enzymatic attacks mainly occur from the front of the molecule, while its posterior part remains relatively stable [7].

Researchers also explored modified versions of Semax to understand what makes it susceptible to metabolic breakdown. Replacing the N-terminal methionine with alanine, glycine, or threonine yielded Semax analogs more resistant to enzymatic action than the original [8]. Furthermore, a version of Semax with a chemical modification known as acetylation at its N-terminal end – known as Ac-Semax – exhibited an altered degradation pattern and different biological properties, although it did not improve cell protection against copper-induced toxicity [9].

The concept of synactone is essential for understanding why Semax metabolism is pharmacologically significant. The metabolic cascade from Semax to HFPGP to PGP does not represent simple inactivation; it generates a sequence of biologically active molecules. Each of these interacts with overlapping, yet distinct, binding sites on the surface of neurons [10]. Of all the degradation fragments studied, HFPGP – the first and primary degradation product – demonstrated the strongest ability to compete for the same binding sites as the original Semax molecule [10]. This means that as Semax is cleared from the system, its first degradation product effectively takes over its action, prolonging the total duration of pharmacological effect.

What is the bioavailability of Semax with different routes of administration?

Bioavailability refers to the amount of a administered substance that actually reaches its target in an active form. For Semax, the route of administration is of significant importance – not only for the quantity reaching the brain but also for the effects that are induced.

Nasal administration – administration through the nose – is both clinically standard and the most pharmacokinetically effective method of delivering Semax to the brain. As described above, this route delivers Semax directly to the brain via the olfactory pathways, completely bypassing the bloodstream.

Direct pharmacokinetic comparisons between nasal and subcutaneous administration in controlled studies are limited in the available literature. However, behavioral and pharmacodynamic studies—measuring actual effects rather than blood levels—provide indirect information. Studies comparing intraperitoneal injection with nasal administration have shown that the nasal route was more effective in improving learning in memory tasks, whereas intraperitoneal injection was needed to elicit analgesic effects that nasal administration did not achieve [11].

This route-of-administration-dependent difference in effects suggests that both methods result in different body distribution patterns. Intranasal administration favors high concentrations in the brain, while injection leads to broader systemic distribution, also reaching peripheral tissues and receptors outside the brain [11]. The better cognitive effects of intranasal Semax compared to injection are consistent with data on rapid brain penetration, confirming detectable levels in the brain as early as 2 minutes after intranasal administration [1].

In the case of oral administration – swallowing Semax – no published pharmacokinetic studies have investigated its absorption from the gastrointestinal tract. Given that peptides are generally rapidly degraded by digestive enzymes in the stomach and intestines before they can be absorbed, the bioavailability of intact Semax molecules after oral administration is likely negligible without specialized protective delivery systems. The C-terminal fragment of PGP may exhibit some ability to survive digestion due to the known stability of this class of peptides, however, this has not been directly confirmed in published research [12].

How long do the effects of Semax last?

The duration of Semax's effects varies significantly depending on the measured effect. It ranges from a few hours for acute changes in neurotransmitter activity to several days or even weeks for effects mediated by neurotrophin signaling and changes in gene expression.

In the case of neurotransmitter effects, extracellular levels of 5-HIAA —a serotonin breakdown product reflecting the activity of the serotonergic system—remained elevated to approximately 180% of the baseline value for 1–4 hours following a single injection of Semax in rats [13]. This indicates a sustained neurochemical effect lasting several hours after a single dose.

In the case of neurotrophic effects – concerning BDNF and NGF, proteins that support the growth and survival of brain cells – the picture is more dynamic. Changes in BDNF gene activity appeared as early as 20 minutes after intranasal administration in rats, reached significant levels after 90 minutes, and returned close to baseline values approximately 8 hours after administration in the hippocampus. The frontal cortex showed a slightly different temporal pattern [2].

However, the effects of BDNF do not end when BDNF levels return to baseline. BDNF works by activating its receptor – TrkB – which then initiates a cascade of intracellular signaling processes. These downstream signaling processes last much longer than the period of elevated BDNF levels themselves.

In ischemic stroke patients treated with Semax, plasma BDNF levels remained elevated throughout the study observation period, suggesting that repeated dosing results in sustained neurotrophic elevation rather than a series of transient peaks [14]. Earlier Russian clinical literature also reported that Semax effects on cognitive functions and resistance to hypoxic conditions in humans persisted for 20–24 hours after a single intranasal dose of 0.015–0.050 mg/kg [15]. This duration of action significantly exceeds what would be expected based on the pharmacokinetics of the intact molecule in the blood and reflects neurotrophic and gene-regulatory mechanisms that outlive direct peptide receptor interactions.

Does Semax accumulate in the body with regular use?

No published studies have directly investigated whether Semax accumulates in tissues or if its receptors become desensitized—meaning less reactive over time—with regular use. However, based on available evidence, Semax does not appear to cause the progressive accumulation seen with many small molecule drugs that are slowly eliminated.

As a peptide, Semax undergoes rapid enzymatic breakdown in biological fluids. This degradation profile makes significant accumulation in tissues with regular use pharmacokinetically unlikely. In studies of chronic administration to rats for 10–14 days, persistent and progressive behavioral effects—including anxiolytic and antidepressant-like actions—were observed without any signs of tolerance or waning response over time. The authors attributed these sustained effects to progressive activation of the serotonergic system and a sustained increase in BDNF [16].

In clinical stroke studies, repeated administration of Semax over two ten-day treatment courses maintained elevated plasma BDNF levels throughout the observation period, consistent with sustained pharmacological engagement rather than receptor desensitization or trophic depletion [14].

The formulation of Semax based on phospholipid nanoparticles was also investigated – a delivery system that encapsulates the peptide with small fat molecules, protecting it from degradation [17]. This approach could theoretically alter the pharmacokinetic profile by slowing down degradation and maintaining active Semax in tissues for a longer period. However, no clinical pharmacokinetic data for this formulation have been published to date.

Generally speaking, while the lack of formal studies on accumulation is a recognized limitation, available functional data do not suggest progressive accumulation or the development of tolerance with short-term regular administration.

Key limitations of Semax pharmacokinetic studies

Interpreting available pharmacokinetic data for Semax, it is important to keep in mind several significant limitations.

Firstly, virtually all direct pharmacokinetic measurements—including brain penetration rates, estimated half-lives, and metabolite identification—have come from rat studies using radiolabeled peptides. The direct translation of these findings to human pharmacokinetics is fraught with significant uncertainty, as humans and rats may process compounds differently.

Secondly, no published pharmacokinetic studies in humans have measured Semax blood concentrations over time under controlled conditions. This means that the precise values for half-life in humans, percentage of bioavailability, and volume of distribution—a measure of how widely a substance spreads throughout the body's tissues—remain unknown.

Third, because the breakdown products of Semax – HFPGP and PGP – retain their own biological activity, conventional pharmacokinetic assessments based solely on parent molecule concentrations significantly underestimate the actual biological duration of action. Measuring only Semax in the blood provides an incomplete picture of the true duration of pharmacological effects.

Fourth, route-dependent differences in Semax effects suggest that its pharmacokinetic behavior differs significantly between nasal, intraperitoneal, and subcutaneous administration. These differences have not yet been fully characterized in the published literature.

Future studies using modern analytical techniques – such as LC-MS/MS, a highly sensitive method for measuring specific molecules in biological fluids – conducted in humans with different routes of administration would significantly broaden the scientific understanding of Semax pharmacokinetics.

Disclaimer

This article is intended solely for educational, informational, and scientific purposes and should not be interpreted as medical advice, a diagnosis, a treatment recommendation, or a claim regarding the efficacy of Semax in the treatment of any medical condition. Semax remains an investigational compound in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article comes from preclinical animal studies and a limited number of clinical trials in humans. Additional, well-designed clinical trials are needed to more accurately determine the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans. Anyone considering the use of any experimental peptides should consult a qualified healthcare professional.

References

1. Shevchenko, K. V., Nagaev, I. Yu., Alfeeva, L. Yu., Andreeva, L. A., Kamenskiĭ, A. A., Levitskaia, N. G., Shevchenko, V. P., Grivennikov, I. A., & Miasoedov, N. F. (2006). Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorganic Chemistry, 32(1), 64–70. https://doi.org/10.1134/s1068162006010055
2. Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35. https://doi.org/10.1007/s12031-009-9270-z
3. Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
4. Dolotov, O. V., Zolotarev, Yu. A., Dorokhova, E. M., Andreeva, L. A., Alfeeva, L. Yu., Grivennikov, I. A., & Miasoedov, N. F. (2004). The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Bioorganic Chemistry, 30(3), 241–246. https://doi.org/10.1023/b:rubi.0000030127.46845.f0
5. Potaman, V. N., Alfeeva, L. Y., Kamensky, A. A., Levitzkaya, N. G., & Nezavibatko, V. N. (1991). N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes. Biochemical and Biophysical Research Communications, 176(2), 741–746. https://doi.org/10.1016/s0006-291x(05)80247-5
6. Zolotarev, Yu. A., Dadaian, A. K., Dolotov, O. V., Kozik, V. S., Kost, N. V., Sokolov, O. Yu., Dorokhova, E. M., Meshavkin, V. K., Inozemtseva, L. S., Gabaeva, M. V., Andreeva, L. A., Alfeeva, L. Yu., Pavlov, T. S., Badmaeva, K. E., Badmaeva, S. E., Bakaeva, Z. V., Kopylova, G. N., Samonina, G. E., Vas’kovskiĭ, B. V., Grivennikov, I. A., Zozulia, A. A., & Miasoedov, N. F. (2006). Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation. Bioorganic Chemistry, 32(2), 183–191. PMID: 16637290 https://pubmed.ncbi.nlm.nih.gov/16637290/
7. Shevchenko, K. V., V’iunova, T. V., Nagaev, I. Yu., Andreeva, L. A., & Miasoedov, N. F. (2013). Proteolysis of simple glyprolines by leucine aminopeptidase and enzymes from nasal slime, brain membranes, and rat blood. Russian Journal of Bioorganic Chemistry, 39(3), 320–325. https://doi.org/10.1134/s1068162013030151
8. Shevchenko, K. V., V’iunova, T. V., Nagaev, I. Yu., Andreeva, L. A., Alfeeva, L. Yu., & Miasoedov, N. F. (2011). Proteolysis of semax analogues with different N-terminal amino acids by aminopeptidases. Russian Journal of Bioorganic Chemistry, 37(4), 475–482. https://doi.org/10.1134/s1068162011040133
9. Magrì, A., Tabbì, G., Giuffrida, A., Pappalardo, G., Satriano, C., Naletova, I., Nicoletti, V. G., & Attanasio, F. (2016). Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry, 164, 59–69. https://doi.org/10.1016/j.jinorgbio.2016.08.013
10. Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2017). Synacton and individual activity of synthetic and natural corticotropins. Journal of Molecular Recognition, 30(5). https://doi.org/10.1002/jmr.2597
11. Manchenko, D. M., Glazova, N. Yu., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Nootropic and analgesic effects of Semax following different routes of administration. I.M. Sechenov Physiological Journal of Russia, 96(10), 1014–1023. PMID: 21268834
12. Ashmarin, I. P., Samonina, G. E., Lyapina, L. A., Kamenskii, A. A., Levitskaya, N. G., Grivennikov, I. A., Dolotov, O. V., Andreeva, L. A., & Myasoedov, N. F. (2005). Natural and hybrid („chimeric”) stable regulatory glyproline peptides. Pathophysiology, 11(4), 179–185. https://doi.org/10.1016/j.pathophys.2004.10.001
13. Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
14. Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
15. Ashmarin, I. P., Nezavibat’ko, V. V., Miasoedov, N. F., Kamenskii, A. A., Grivennikov, I. A., Ponomareva-Stepnaya, M. A., Andreeva, L. A., Kaplan, A. Ya., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745
16. Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Sechenov Physiological Journal of Russia, 93(6), 661–669. PMID: 17850024
17. Shevchenko, K. V., Khrapko, A. P., Schwets, V. I., & Myasoyedov, N. F. (2009). The use of phospholipid nanoparticles for increasing Semax resistance in various proteolytic biological media. Doklady Biological Sciences, 429, 505–507. https://doi.org/10.1134/s0012496609060076